Patients in cluster 16 (identified by Apo-AI and Apo-AII) had a relatively low risk of stroke recurrence at 3 months (HR, 0.119; 95% CI 0.017–0.850, P = 0.034). The gene discussed is APOA2; the disease is stroke disorder.